Titre : | Cannabidiol products are everywhere, but should people be using them? (2019) |
Auteurs : | R. RUBIN |
Type de document : | Article : Périodique |
Dans : | Journal of the American Medical Association (Vol.322, n°22, December 10, 2019) |
Article en page(s) : | 2156-2158 |
Langues: | Anglais |
Discipline : | SAN (Santé publique / Public health) |
Mots-clés : |
Thésaurus mots-clés CANNABINOIDES ; CANNABIDIOL ; USAGE THERAPEUTIQUE ; EFFICACITE ; LEGISLATIONThésaurus géographique ETATS-UNIS |
Résumé : |
General internist Brent Bauer, MD, sees patients at the Mayo Clinic in Rochester, Minnesota, one of the most esteemed medical centers in the world.
And yet, some of his patients have sought relief from a variety of ills with ubiquitous, unregulated products they can pick up at 7/Eleven or order online (although not from Amazon, whose selling guidelines prohibit them). The products' labels say they contain cannabidiol, or CBD, 1 of more than 100 identified compounds in the cannabis plant, commonly known as marijuana. Unlike tetrahydrocannabinol (THC), the other well-known cannabinoid in cannabis, CBD doesn't make users high. Bauer's patients take CBD products to reduce pain, sleep better, and ease anxiety. [Extract] |
Domaine : | Drogues illicites / Illicit drugs |
Lien : | https://doi.org/10.1001/jama.2019.17361 |
Accueil